Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0001099800
$90.09
+1.91% · live
Updated
$52.32B market value
From Edwards Lifesciences Corp's FY2025 10-K, filed Feb 25, 2026 · read the filing
Edwards Lifesciences makes medical devices and equipment. It took in $6.07B last year, which makes it a mid-sized company. Of every dollar it sells, about 18 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by 3 insiders, not under a pre-arranged plan.
$3.2M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From Edwards Lifesciences Corp's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$4.17B → $1.07B
Profit margin
76.7% → 17.7%
Free cash flow
$289.9M → $1.33B
Earnings per share
$7.09 → $1.85
Measured against FY2024, from the 10-K filed Feb 25, 2026
Deteriorated: -74.3%
$4.17B to $1.07BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
EW rose 1.91% on the latest quote. The average Health Care company tracked here moved +1.61%, and the S&P 500 −1.04%. That is in line with its sector and 3.0 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 14% a year for the next 10 years. Over the last 10 years it grew by about 12% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 18 cents of every dollar of sales as profit, earning $1.07B last year.
Slowly. Sales grew 11.5% last year.
No — it holds more cash than debt, with $2.34B left over after paying off every borrowing. For every $1 it owes, it owns $4.08 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.07B and generated $1.60B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 25, 2026Filing for FY2025 | FY202410-K · Feb 28, 2025Filing for FY2024 | FY202310-K · Feb 28, 2025Filing for FY2023 | FY202210-K · Feb 28, 2025Filing for FY2022 | FY202110-K · Feb 12, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | +11.5% |
| Cost of revenue | $1.33B | $1.12B | $978.4M | $723.7M | $1.25B | +19.4% |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | +9.5% |
| Gross marginGross profit ÷ revenueWhat is this? | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% | −1.4 pts |
| Selling, general and administrative | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | +16.5% |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | −8.3% |
| Operating marginOperating income ÷ revenueWhat is this? | 20.8% | 25.3% | 26.1% | 33.6% | 32.3% | −4.5 pts |
| Interest expense | $20.4M | $19.8M | $17.6M | $19.2M | $18.4M | +3.0% |
| Income before tax | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | −17.8% |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | −74.3% |
| Net marginNet income ÷ revenueWhat is this? | 17.7% | 76.7% | 28.0% | 34.1% | 28.7% | −59.1 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $1.85 | $7.09 | $2.33 | $2.50 | $2.41 | −73.9% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| EWEdwards Lifesciences Corp · this page | 9.0/10 | 6/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 619 shares at $72.68 ($45.0K)
Holds 40,653 shares after this filing.
Sold on the open market — 619 shares at $85.65 ($53.0K)
Holds 40,034 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2026
Revenue +13.6% · Operating margin +2.6 pts · Operating income +24.8% — against Q2 FY2025
Read the filingWrite down why you are following Edwards Lifesciences Corp, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 7 subsidiaries named in its 10-K, incorporated across 6 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Source: of the 10-K filed 2026-02-25. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from EW's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 25, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 6/9 | 10-K, filed Feb 25, 2026 |
| FY2024 | 7.0 | 6/9 | 10-K, filed Feb 28, 2025 |
| FY2023 | 8.0 | 5/9 | 10-K, filed Feb 12, 2024 |
| FY2022 | 9.0 | 6/9 | 10-K, filed Feb 13, 2023 |
| FY2021 | 10.0 | 8/9 | 10-K, filed Feb 14, 2022 |
| FY2020 | 9.0 | 6/9 | 10-K, filed Feb 12, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
11.98
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −59.1 pts
76.7% to 17.7%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +360.5%
$289.9M to $1.33BCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -73.9%
$7.09 to $1.85Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: −4.5 pts
25.3% to 20.8%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +11.5%
$5.44B to $6.07BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +9.5%
$4.32B to $4.73BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: -8.3%
$1.38B to $1.26BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −1.4 pts
79.5% to 78.0%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: -1.3%
588.6M to 580.7MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 4, 2026 — read it.
Improved: +24.8%
$411.2M to $513.2MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -27.4%
$333.2M to $241.9MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −7.8 pts
21.7% to 13.9%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -26.0%
$0.57 to $0.42Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +13.6%
$1.53B to $1.74BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +13.5%
$1.19B to $1.35BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +2.6 pts
26.8% to 29.5%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: -11.2%
$3.27B to $2.91BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -1.9%
587.9M to 576.6MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 4, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: −9.2 pts
23.1% to 13.9%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -36.5%
$380.7M to $241.9MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: -36.4%
$0.66 to $0.42Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +18.9%
$2.45B to $2.91BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +5.6%
$1.65B to $1.74BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +7.5%
$477.6M to $513.2MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 11% and 16%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 38 analysts covering this company, as of . Their views, not this site's.
Of 38 analysts publishing on this company, 13 say strong buy, 18 say buy and 7 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.6% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 42.0x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 11.5% |
| 17.7% |
| 48.73x |
| 0.32x |
| ABTABBOTT LABORATORIES | 9.0/10 | 6/9 | 5.7% | 14.7% | 27.25x | 0.66x |
|---|
| ISRGINTUITIVE SURGICAL INC | 10.0/10 | 7/8 | 20.5% | 28.4% | 55.19x | 0.14x |
|---|
| SYKSTRYKER CORP | 9.0/10 | 6/9 | 11.2% | 12.9% | 36.10x | 1.13x |
|---|
| BSXBOSTON SCIENTIFIC CORP | 10.0/10 | 8/9 | 19.9% | 14.4% | 23.48x | 0.80x |
|---|
| BDXBECTON DICKINSON & CO | 7.0/10 | 6/9 | 8.2% | 7.7% | 34.09x | 1.18x |
|---|
| IDXXIDEXX LABORATORIES INC /DE | 9.0/10 | 8/9 | 10.4% | 24.6% | 42.64x | 1.09x |
|---|
| RMDRESMED INC | 9.0/10 | 8/9 | 9.9% | 26.9% | 23.96x | 0.36x |
|---|
| Median of peers | 9.0/10 | — | 10.4% | 14.7% | 34.09x | 0.80x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Had shares withheld to cover taxes — 253 shares at $84.37 ($21.3K)
Holds 14,615 shares after this filing.
Had shares withheld to cover taxes — 355 shares at $86.77 ($30.8K)
Holds 19,939 shares after this filing.
Had shares withheld to cover taxes — 568 shares at $84.37 ($47.9K)
Holds 19,371 shares after this filing.
Exercised stock options — 619 shares at $72.68 ($45.0K)
Holds 40,653 shares after this filing.
Sold on the open market — 619 shares at $87.51 ($54.2K)
Holds 40,034 shares after this filing.
Had shares withheld to cover taxes — 398 shares at $86.77 ($34.5K)
Holds 43,926 shares after this filing.
Sold on the open market — 544 shares at $91.06 ($49.5K)
Holds 14,868 shares after this filing.
Sold on the open market — 2,644 shares at $89.98 ($237.9K)
Holds 17,984 shares after this filing.
Exercised stock options — 31,800 shares at $72.68 ($2.3M)
Holds 76,124 shares after this filing.
Sold on the open market — 1,154 shares at $91.76 ($105.9K)
Holds 74,970 shares after this filing.
Sold on the open market — 30,646 shares at $90.99 ($2.8M)
Holds 44,324 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 544 shares ($49.5K) on or after .
Shares originally obtained via Restricted Stock Lapse.
Filed notice to sell 2,644 shares ($237.9K) on or after .
Shares originally obtained via Restricted Stock Lapse.
Filed notice to sell 31,800 shares ($2.9M) on or after .
Shares originally obtained via Employee Stock Option Exercise.
Filed notice to sell 1,240 shares ($113.4K) on or after .
Shares originally obtained via Restricted Stock Lapse.
Filed notice to sell 1,857 shares ($170.9K) on or after .
Shares originally obtained via Employee Stock Option Exercise - See Remarks.
Filed notice to sell 50,000 shares ($4.6M) on or after .
Shares originally obtained via RSU / PSU - See Remarks.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Published results
Had a director or senior officer leave or join · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +16.7% · Operating margin +1.0 pts · Free cash flow turned negative — against Q1 FY2025
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Revenue +11.5% · Operating margin −4.5 pts · Profit -74.3% — against FY2024
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +14.7% · Operating margin −6.1 pts · Profit -90.5% — against Q3 FY2024
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2025
Revenue +11.9% · Profit margin −5.0 pts · Cash +99.0% — against Q2 FY2025
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingPublished results
Read the filingHad a director or senior officer leave or join · Held a shareholder vote
Read the filingCoverage from the last 30 days
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
Yahoo ·
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
Yahoo ·
Is This the Right Time to Hold EW Stock in Your Portfolio?
Yahoo ·
Edwards secures FDA approval for tricuspid valve repair system
Yahoo ·
FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
Yahoo ·
Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales
Yahoo ·
9 Health Care Stocks Whale Activity In Today’s Session
Benzinga ·
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Yahoo ·
Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert
Yahoo ·
Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue
Benzinga ·
Bet on These Healthcare ETFs to Benefit From the Aging US Population
Yahoo ·
Edwards Lifesciences Earnings Preview: What to Expect
Yahoo ·
Primary sources and further research